JWA
PCVX icon

JFS Wealth Advisors’s Vaxcyte PCVX Stock Holding History

JFS Wealth Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$291 Buy
+5
New +$272 ﹤0.01% 2069
2025
Q1 		– Sell
-1
Closed -$82 – 1978
2024
Q4 		$82 Buy
+1
New +$99 ﹤0.01% 1895

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

JFS Wealth Advisors's PCVX Position: Q2 2026 in Review

JFS Wealth Advisors opened a new position in Vaxcyte (PCVX) in Q2 2026: 5 shares worth $291. The stake represents ﹤0.01% of the portfolio and ranks #2069 among its holdings. This is a return to the name: JFS Wealth Advisors previously reported a position in PCVX as recently as Q4 2024.

JFS Wealth Advisors first reported a position in PCVX in Q4 2024 and has held it in 2 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • JFS Wealth Advisors held 5 shares of Vaxcyte worth $291 as of Q2 2026.
  • Vaxcyte was a new JFS Wealth Advisors position in Q2 2026.
  • Vaxcyte made up ﹤0.01% of JFS Wealth Advisors's portfolio in Q2 2026, its #2069 holding.
  • JFS Wealth Advisors first reported a position in Vaxcyte in Q4 2024 and has held it in 2 quarters since.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on JFS Wealth Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.